Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598247 | 0.87 | IRAK4 (0.65) | IRAK4ROCK2ROCK1IRAK1PIM1 | |
| SCHEMBL30501418 | 0.87 | IRAK4 (0.65) | IRAK4ROCK2ROCK1IRAK1PIM1 | |
| SCHEMBL20598549 | 0.86 | CHEK1 (0.52) | IRAK4PIM1PIM3 | |
| SCHEMBL20598451 | 0.85 | IRAK4 (0.63) | IRAK4ROCK2ROCK1IRAK1PIM1 | |
| SCHEMBL20598567 | 0.84 | IRAK4 (0.66) | IRAK4ROCK2ROCK1IRAK1PIM1 | |
| SCHEMBL20598593 | 0.84 | PIM1 (0.43) | IRAK4NTSR1PIM1PIM3 | |
| SCHEMBL30501473 | 0.84 | PIM1 (0.43) | IRAK4NTSR1PIM1PIM3 | |
| SCHEMBL20597991 | 0.84 | CSF1R (0.44) | IRAK4ROCK2ROCK1 | |
| SCHEMBL30501233 | 0.84 | NTSR1 (0.43) | IRAK4ROCK2ROCK1NTSR1 | |
| SCHEMBL20598190 | 0.82 | IRAK4 (0.72) | IRAK4IRAK1PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | claimed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | claimed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | claimed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | claimed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | claimed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885ROCK2 610/4885ROCK1 535/4885 |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885ROCK2 610/4885ROCK1 535/4885 |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885ROCK2 801/4885ROCK1 403/4885 |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885ROCK2 610/4885ROCK1 535/4885 |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885ROCK2 646/4885ROCK1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.